Read Larry Connors' blog – Short Term Trading Strategies
According to the company, Attain Ability has the thinnest lead body of any left-heart lead currently available, providing physicians with a tool to deliver therapy directly to hard-to-reach areas of the heart. Attain Ability incorporates insulation material developed by NASA Langley Research Center that was previously evaluated for space applications, high-performance engines and harsh environments.
The company said that this application marks the first time a NASA-developed material has been used in this kind of implantable medical device.
"Attain Ability is the latest innovation in our long-term strategy to provide physicians with a broad portfolio of leads and delivery systems to meet the unique needs of their patients," said Pat Mackin, president of the Cardiac Rhythm Disease Management business and senior vice president at Medtronic. "We're proud to partner with NASA, another innovation leader, to provide physicians with a unique, technology-based solution to assist physicians with optimal lead placement in heart failure patients."
Navigating a lead through the intricate curves of the heart's anatomy to place the lead in the ideal location on the left ventricle is recognized by physicians as the most challenging aspect of implanting CRT devices. The compact design afforded by the NASA insulation material makes this the thinnest left-heart lead body on the market. Its design allows physicians to choose between different sites in order to deliver optimal therapy. Additionally, Attain Ability can be delivered by an inner catheter, the Attain Select II. This feature helps physicians place the lead directly in difficult-to-reach areas of the heart. A clinical study involving 190 patients at 25 centers in the United States and Canada showed physicians were successful in placing the Attain Ability lead 96.4 percent of the time.
"The unique design of the Attain Ability lead provides clinicians with a greater degree of flexibility in left ventricular lead placement," said Brian Ramza, M.D., Ph.D, director of Electrophysiology Laboratory Services at the Mid America Heart Institute, Saint Luke's Hospital, Kansas City, Mo., and principal investigator of the Attain Ability clinical trial. "The lead provides the flexibility of multi-site pacing from small veins because of its design, therefore, truly having the potential to improve outcomes for patients with unique needs."
In CRT, a stopwatch-sized device is implanted into the chest and connected by leads to the heart's left and right ventricles. Through electrical impulses, the device resynchronizes heartbeats, allowing blood to be pumped more effectively through the body. The company added that CRT defibrillators (CRT-D) incorporate additional lifesaving therapy to quickly terminate an abnormally fast, life-threatening heart rhythm. CRT and CRT-D have become increasingly important therapeutic options for patients with moderate and severe heart failure since Medtronic first began clinical evaluation of its CRT systems in 1997.
Medtronic, Inc. is the global provider of medical technology.
((Comments on this story may be sent to health@closeupmedia.com))
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
